Troubled Biotechs: Alexza, Synvista, Alseres, Bionovo
This article was originally published in The Pink Sheet Daily
Executive Summary
Alexza says its restructuring should keep it operating well into 2010, but three other companies probably have less time.
You may also be interested in...
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Symphony's Project Financing Model Adapts
As Wall Street fails to significantly reward companies with strong clinical news, the fall-out also affects the project financiers, like Symphony Capital -- an increasingly important alternative to traditional equity or alliance financing. On one hand, the hard times make Symphony's expensive-looking capital increasingly attractive to biotechs, including companies that once would have had plenty of other financing alternatives. On the other, Symphony's model is shifting more toward equity investing. It's still financing projects, but it's padding its upside with a lot more cheap stock.